Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 753 across all filing types
Latest filing 2025-04-10 Management Reports
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
2024年度独立董事述职报告（曹红中）
Management Reports Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report". It is a detailed report by an independent director about their duties, attendance at meetings, supervision of company governance, and other oversight activities during the year 2024. The content includes descriptions of board meetings, committee meetings, oversight of financial reports, internal controls, related party transactions, auditor changes, and other governance matters. This type of document is a management or director report focusing on the independent director's role and activities over the year. It is not an annual report (10-K), audit report (AR), or a simple announcement. It is a management report specifically from an independent director, which fits best under the category of Management Reports (MDA). The document length (6018 characters) and detailed content confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is Management Reports (MDA) with high confidence.
2025-04-10 Chinese
2024年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2024 by 科兴生物制药股份有限公司. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024, including financial and non-financial internal control defects, audit opinions, and compliance with regulatory requirements. The content is focused on internal control evaluation rather than full financial statements or annual performance. It is a specialized report on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR) as it includes audit opinions and internal control assessment results but is not a full Annual Report (10-K) or Interim Report (IR). The document length is about 5206 characters, which is sufficient to be a full report rather than a brief announcement. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2024
2025-04-10 Chinese
第二届董事会第二十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 22nd meeting of the 2nd Board of Directors of 科兴生物制药股份有限公司. It includes approvals of various reports and proposals related to the 2024 fiscal year, such as the Board's work report, General Manager's report, Audit Committee's report, independent directors' reports, internal control evaluation, financial statements, profit distribution plan, and fundraising usage. It also mentions submission of these reports to the shareholders' meeting and references to the full 2024 Annual Report and related documents published on the Shanghai Stock Exchange website. The document is comprehensive and contains substantive content about the company's governance and financial matters for the year 2024, indicating it is not merely an announcement but a detailed board meeting resolution document. This type of document fits best under the category of Board/Management Information (MANG), as it primarily concerns board meeting resolutions and management reports rather than the full annual report itself or a simple announcement of report publication.
2025-04-10 Chinese
2024年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Audit Report" for the fiscal year 2024, issued by a registered accounting firm (Grant Thornton) to the shareholders of 科兴生物制药股份有限公司. It discusses the audit of the effectiveness of internal controls over financial reporting as of December 31, 2024, and provides an audit opinion on the internal control system. The content focuses on the audit of internal controls rather than the full annual financial statements or management discussion. The document length is 3559 characters, which is relatively short but contains substantive audit opinion content. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-10 Chinese
董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors. It references regulatory guidelines about independent directors and their independence evaluation. The content is focused on governance and compliance with listing rules, specifically about board members' independence. It does not contain financial data, audit results, or financial performance information. It is not an announcement of a report publication but a governance-related statement. Therefore, the document fits best under Governance Information (CGR). The document length is short and focused on governance matters, not a full report or announcement.
2025-04-10 Chinese
2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled '2024 年年度报告摘要' which translates to '2024 Annual Report Summary'. It contains detailed information about the company's business, products, financial performance, risk factors, profit distribution plans, and other comprehensive data typical of an annual report. The document length is substantial (15,000 characters), indicating it is not a mere announcement or summary notice. It includes management discussion and analysis, risk factors, and detailed business descriptions, which are characteristic of an Annual Report (10-K). There is no indication that this is a certification, proxy, or other filing type. Therefore, the document is classified as an Annual Report (10-K). FY 2024
2025-04-10 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.